dc.contributor
Institut Català de la Salut
dc.contributor
[Nozawa K] Department of Advanced Clinical Research and Development, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. Department of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. [Sawaki M] Department of Breast Oncology, Nagoya Medical Center, Nagoya, Japan. [Uemura Y] Biostatistics Section, Department of Data Science, Center of Clinical Sciences, National Center for Global Health and Medicine, Shinjuku, Japan. [Tsuneizumi M] Department of Breast Surgery, Shizuoka General Hospital, Shizuoka, Japan. [Takano T] Department of Breast Medical Oncology, The Cancer Institute Hospital of JFCR, Koto, Japan. [Gondo N] Department of Breast and Thyroid Surgical Oncology, Sagara Hospital, Kagoshima, Japan. [Villacampa G] Statistics Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Nozawa, Kazuki
dc.contributor.author
Sawaki, Masataka
dc.contributor.author
Uemura, Yukari
dc.contributor.author
Tsuneizumi, Michiko
dc.contributor.author
Takano, Toshimi
dc.contributor.author
Gondo, Naomi
dc.contributor.author
Villacampa Javierre, Guillermo
dc.date.accessioned
2026-03-05T23:45:38Z
dc.date.available
2026-03-05T23:45:38Z
dc.date.issued
2026-03-03T13:22:24Z
dc.date.issued
2026-03-03T13:22:24Z
dc.date.issued
2025-11-04
dc.identifier
Nozawa K, Sawaki M, Uemura Y, Tsuneizumi M, Takano T, Gondo N, et al. HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy. Nat Commun. 2025 Nov 4;16:9585.
dc.identifier
http://hdl.handle.net/11351/14289
dc.identifier
10.1038/s41467-025-65599-x
dc.identifier
001608931300002
dc.identifier.uri
https://hdl.handle.net/11351/14289
dc.description.abstract
Older patients; HER2-positive breast cancer; Chemotherapy
dc.description.abstract
Pacientes mayores; Cáncer de mama HER2 positivo; Quimioterapia
dc.description.abstract
Pacients grans; Càncer de mama HER2 positiu; Quimioteràpia
dc.description.abstract
Older adults with HER2-positive early breast cancer are underrepresented in clinical trials, and the benefit of chemotherapy in this population remains uncertain. We evaluated the HER2DX genomic assay within the randomized RESPECT trial (NCT01104935), which compared adjuvant trastuzumab with or without chemotherapy in patients aged 70–80 years. In this prespecified translational analysis (Trans-RESPECT), HER2DX scores were available for 154 patients. The HER2DX risk score classified 74.0% as low risk and 26.0% as high risk. Ten-year relapse-free and overall survival were higher in the low-risk group. HER2DX remained independently associated with overall survival in multivariable analysis. The HER2DX immune, luminal, and proliferation signatures that compose the risk score were also prognostic. While the HER2DX pCR score was not prognostic overall, exploratory subgroup analyses suggested a potential survival benefit from chemotherapy in the pCR-high group. HER2DX offers prognostic value and may guide chemotherapy use in older patients with HER2-positive early breast cancer. Clinical Trial Information NCT01104935
dc.description.abstract
This study was funded by CSPOR, Chugai Pharmaceutical Co. Ltd and Reveal Genomics.
dc.format
application/pdf
dc.publisher
Nature communications
dc.relation
Nature Communications;16
dc.relation
https://doi.org/10.1038/s41467-025-65599-x
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Persones grans
dc.subject
Quimioteràpia combinada
dc.subject
Mama - Càncer - Quimioteràpia
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols
dc.subject
NAMED GROUPS::Persons::Age Groups::Adult::Aged
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada
dc.subject
DENOMINACIONES DE GRUPOS::personas::Grupos de Edad::adulto::anciano
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.title
HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
